NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models

Clinical Cancer Research

Volumn 22, Issue 3, 2016, Pages 680-690

  Charych, Deborah H ^a   Hoch, Ute ^a   Langowski, John L ^a   Lee, Steve R ^a   Addepalli, Murali K ^a   Kirk, Peter B ^a   Sheng, Dawei ^a   Liu, Xiaofeng ^a   Sims, Paul W ^a   VanderVeen, Laurie A ^a   Ali, Cherie F ^a   Chang, Thomas K ^a   Konakova, Marina ^a   Pena, Rhoneil L ^a   Kanhere, Rupesh S ^a   Kirksey, Yolanda M ^a   Ji, Chunmei ^a   Wang, Yujun ^a   Huang, Jicai ^a   Sweeney, Theresa D ^a   Kantak, Seema S ^a   Doberstein, Stephen K ^a   more..

^a NEKTAR THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDESLEUKIN; ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; NKTR 214; STAT5 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HYBRID PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MACROGOL DERIVATIVE; NKTR-214; PRODRUG; PROTEIN BINDING; RECOMBINANT PROTEIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BREAST TUMOR; CAPILLARY LEAK SYNDROME; CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLON TUMOR; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; EC50; FEMALE; HUMAN; HUMAN CELL; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; LUNG EDEMA; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MACACA FASCICULARIS; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR IMMUNITY; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CONFORMATION; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL MELANOMA; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; MOLECULAR MODEL; NEOPLASMS; PATHOLOGY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CTLA-4 ANTIGEN; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; INTERLEUKIN-2; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA, EXPERIMENTAL; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NEOPLASMS; POLYETHYLENE GLYCOLS; PRODRUGS; PROTEIN BINDING; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; T-LYMPHOCYTES, REGULATORY; TUMOR BURDEN;

EID: 84958979893     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1631     Document Type: Article

References (37)

1. Pennock G, Chow L. The evolving role of immune checkpointe inhibitors in cancer treatment. Oncologist 2015;20:1-11.
2. Rosenberg SA. Raising the bar: The curative potential of human cancer immunotherapy. Sci Transl Med 2012;4:127ps8.
3. Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008;14:5610-8.
4. Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: A retrospective analysis of response and survival in patients treated in the Surgery Branch at theNationalCancer Institute between 1986 and 2006. Cancer 2008;113:293-301.
5. Atkins MB, Lotze MT, Dutcher JP, Fisher RI,Weiss G, Margolin K, et al. Highdose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16.
6. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2-Identification of the antigens mediating response. Ann Surg 1998;228:307-19.
7. Wang X, Rickert M, Garcia KC. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science 2005; 310:1159-63.
8. Margolin K. Cytokine therapy in cancer. Expert Opin Biol Ther 2008; 8:1495-505.
9. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 2012;12:180-90.
10. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010;107:4275-80.
11. Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol 2013;25:268-76.
12. Zhou P, Zheng X, Zhang H, Liu Y, Zheng P. B7 blockade alters the balance between regulatory T cells and tumor-reactive T cells for immunotherapy of cancer. Clin Cancer Res 2009;15:960-70.
13. Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y, et al. Tumor-specific human CD4+ regulatory T cells and their ligands: Implications for immunotherapy. Immunity 2004;20:107-18.
14. RickertM,Wang X, Boulanger MJ, Goriatcheva N, Garcia KC. The structure of interleukin-2 complexed with its alpha receptor. Science 2005;308: 1477-80.
15. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-13.
16. UC10-4F10-11 (ATCC- HB-304-) culture method; 2015 [accessed 2015 Jun 29]. Available from http://www.atcc.org/Products/All/HB-304. aspx#culturemethod.
17. Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA. Crystal structure of the IL-2 signaling complex: Paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A 2006;103:2788-93.
18. Gibbons JA, Luo ZP, Hannon ER, Braeckman RA, Young JD. Quantitation of the renal clearance of interleukin-2 using nephrectomized and ureterligated rats. J Pharmacol Exp Ther 1995;272:119-25.
19. Konrad MW, Hemstreet G, Hersh EM, Mansell PW, Mertelsmann R, Kolitz JE, et al. Pharmacokinetics of recombinant interleukin 2 in humans.Cancer Res 1990;50:2009-17.
20. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6.
21. Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS, et al. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 2008;26:2034-9.
22. Anderson JA, Lentsch AB, Hadjiminas DJ, Miller FN, Martin AW, Nakagawa K, et al. The role of cytokines, adhesion molecules, and chemokines in interleukin-2-induced lymphocytic infiltration in C57BL/6 mice. J Clin Invest 1996;97:1952-9.
23. Patel JN,Walko CM. Sylatron: A pegylated interferon for use inmelanoma. Ann Pharmacother 2012;46:830-8.
24. Parveen S, Sahoo SK. Nanomedicine: Clinical applications of polyethylene glycol conjugated proteins and drugs. Clin Pharmacokinet 2006;45: 965-88.
25. Fishburn CS. The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008;97:4167-83.
26. Kunugi K, Yamaoka T. Polymers in nanomedicine. Springer-Verlag, Heidelberg; New York, NY; 2012. p.xi, 281p.
27. Shanafelt AB, Lin Y, Shanafelt MC, Forte CP, Dubois-Stringfellow N, Carter C, et al. A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat Biotechnol 2000;18:1197-202.
28. Margolin K, Atkins MB, Dutcher JP, Ernstoff MS, Smith JW, Clark JI, et al. Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. Clin Cancer Res 2007;13:3312-9.
29. Krieg C, L-etourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A 2010;107:11906-11.
30. Gillies SD, Lan Y, Hettmann T, Brunkhorst B, Sun Y,Mueller SO, et al. A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity. Clin Cancer Res 2011;17:3673-85.
31. Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, et al. Exploiting a natural conformational switch to engineer an interleukin-2superkine'. Nature 2012;484:529-33.
32. Sundstedt A, Celander M, Eriksson E, Torngren M, Hedlund G. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model. J Immunother 2012;35:344-53.
33. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GMCSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006;116:1935-45.
34. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: New immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013;19:5300-9.
35. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
36. Hafalla JC, Claser C, Couper KN, Grau GE, Renia L, De Souza JB, et al. The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology. PLoS Patholog 2012;8:e1002504.
37. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013;73: 3591-603.